Document is current
Any future updates will be listed below
-
Authors
Scholand, Katherine E.
Dellon, Evan S.
- License Information
-
More Information
Article History
Received: 14 January 2026
Accepted: 11 February 2026
First Online: 5 March 2026
Declarations
:
: Dr. Dellon reports research funding from: Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Sanofi, Shire/Takeda, Uniquity; consulting fees from: Abbvie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, Anaptysbio, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Bethanamist, Biocryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Cyted, Domain, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio; and educational grants from: Allakos, Aqilion, Holoclara, Invea. Dr. Scholand has nothing to report.
: Not applicable for this review article.
